drug · small molecule
omadacycline tosylate
Marketedupdated 3mo agoby Paratek Pharmaceuticals Inc🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for skin disease and bacterial pneumonia and 1 investigational indication.
targets
Bacterial 70S ribosome
all catalysts(0)
nothing on the calendar yet
Trials studying omadacycline tosylate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 2, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- Oct 31, 2037method-of-use (U-2576)US 10383884
- Oct 31, 2037method-of-use (U-2576)US 10383884
- Oct 31, 2037method-of-use (U-2576)US 10835542
- Oct 31, 2037method-of-use (U-2576)US 10835542
- Aug 3, 2037method-of-use (U-2444)US 10111890
- Mar 18, 2031formulationUS 93144754.6y
- Oct 24, 2030formulationUS 92657404.2y
- Sep 23, 2030compositionUS 83836104.1y
- Mar 5, 2029method-of-use (U-2449)US 101240142.6y
- Mar 5, 2029method-of-use (U-2449)US 101240142.6y
- Mar 5, 2029formulationUS 92657402.6y
- Mar 5, 2029method-of-use (U-1569)US 97243582.6y
- Mar 5, 2029method-of-use (U-1569)US 97243582.6y
FDA exclusivities (4)
- Oct 2, 2028GAINGAIN Antibiotic (5y)2.1y
- Oct 2, 2028GAINGAIN Antibiotic (5y)2.1y
- Oct 2, 2023NCENew Chemical Entity (5y)
- Oct 2, 2023NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that